Bio-Rad Laboratories

4000 Alfred Nobel Drive
Hercules,  CA  94547

United States
http://www.bio-rad.com/diagnostics
  • Booth: 3339

Profile

Bio-Rad Laboratories is a leading global clinical diagnostics and life sciences company. We are focused on meeting the diagnostic testing needs of our customers in all areas of the hospital and reference laboratories. Bio-Rad delivers on this commitment by offering a broad portfolio of quality products backed by superior service. Bio-Rad holds leadership position in diabetes monitoring, quality control (QC) system, autoimmune testing, HIV test systems, blood bank reagents and instrumentation.


 Press Releases

  • HERCULES, Calif. — January 16, 2017 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, announced today that it has entered into a definitive agreement to purchase RainDance Technologies, Inc. The terms of the acquisition were not disclosed. Bio-Rad expects the transaction to close during the first quarter of 2017. The company will discuss the acquisition further during Bio-Rad’s upcoming fourth-quarter and full-year 2016 financial results conference call.

    Based in Billerica, Massachusetts, RainDance Technologies’ foundational intellectual property portfolio and product lines encompass a wide range of biological reactions in droplets, with applications in life science research and clinical research. These genomic tools provide ultra-sensitive detection of genetic variations in cancer as well as inherited and infectious diseases, enabling research in areas such as non-invasive liquid biopsy.

    “We are pleased to have RainDance join Bio-Rad,” said Norman Schwartz, Bio-Rad President and CEO. “The company’s droplet-based solutions will extend our reach into next generation sequencing applications and strengthen our position in the area of Droplet Digital PCR. We look forward to expanding our offering to provide life science and clinical diagnostics customers with solutions for a wide range of nucleic acid detection applications.”

  • SAN DIEGO and HERCULES, Calif. — January 9, 2017 — Illumina, Inc. (NASDAQ: ILMN) and Bio‑Rad Laboratories, Inc. (NYSE: BIO)(NYSE: BIOb) today announced the launch of the Illumina® Bio-Rad® Single-Cell Sequencing Solution at the J.P. Morgan Healthcare Conference, San Francisco. The comprehensive solution is the first next-generation sequencing (NGS) workflow for single-cell analysis, providing researchers the ability to investigate the coordinated contribution of individual cells in tissue function, disease progression, and therapeutic response.

    Single-cell analysis enables a deep view into the gene expression of individual cells to understand their functions in complex tissues. The solution delivers high-throughput sequencing of thousands of individual cells, traditionally a challenging, costly, and time consuming process. Human development and disease research, fields in which single-cell sequencing is widely applicable, is expected to benefit most from this new offering.

    “Single-cell genomics provides the opportunity to look at stem cells turning into neurons that are lost in diseases like Parkinson’s and amyotrophic lateral sclerosis (also known as Lou Gehrig's disease) with much higher accuracy,” said Clive Svendsen, PhD, Director, Cedars-Sinai Board of Governors Regenerative Medicine Institute in Los Angeles. His laboratory tested the application of the new platform to profile single cells used in modeling neurodegenerative diseases.

    “Using the solution made it possible to detect single cells in a population that was maturing faster than others, allowing us to produce better models of disease,” added Ritchie Ho, PhD, Project Scientist in the Cedars-Sinai Board of Governors Regenerative Medicine Institute and lead researcher for the testing.

    The solution comprises the ddSEQ™ Single-Cell Isolator and SureCell™ WTA 3' Library Prep Kit. Bio-Rad’s best-in-class droplet partitioning technology, Droplet Digital™ technology, is used to isolate and barcode single cells for downstream sequencing on many of Illumina’s leading NGS instruments. The comprehensive workflow solution includes primary and secondary data analysis conducted via the BaseSpace® Informatics Suite, Illumina’s cloud-based genomics computing environment, and tertiary data analysis and visualization with SeqGeq™ from FlowJo, LLC, the market leader in flow cytometry analysis.

    “Through our close collaboration with Illumina we developed a seamless and scalable solution for single-cell analysis,” said Annette Tumolo, Bio-Rad Executive Vice President and General Manager, Digital Biology Group. “We are proud to equip cell biologists and others in the research community with the tools they need to power new discovery.”

    “By offering cell biologists access to technologies that make single-cell analysis cost effective and easy to adopt, we hope to enable scientists to advance complex disease research using gene expression insights,” said Rob Brainin, Vice President and General Manager, Applied Genomics at Illumina. “Our collaboration with Bio-Rad has allowed us to bring this technology to market quickly and empower our customers to unlock the power of the genome to improve human health.” The Illumina® Bio-Rad® Single-Cell Sequencing Solution will begin shipping in early February. For more information about the instruments, reagents, and workflow, visit www.bio-rad.com/ddSEQ.
  • HERCULES, CA – August 3, 2016 – Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, today announced its continued expansion into the molecular diagnostics testing market with the launch of Amplichek™ I quality control, which was recently issued a 510(k) clearance from the U.S. Food and Drug Administration (FDA).

    Amplichek I will be available in August and is the second in a series of infectious disease controls that Bio-Rad has introduced for the molecular diagnostic testing this year. Molecular diagnostics continues to be one of the fastest growing in vitro diagnostics (IVD) markets, estimated to reach $9.3 billion by 2020, according to a 2015 report by research firm MarketsandMarkets.

    “We are pleased to expand our offering of controls for the molecular diagnostics testing market,” said John Hertia, Bio-Rad President, Clinical Diagnostics Group. “The introduction of Amplichek I represents Bio-Rad’s continued commitment to improve laboratory analytical performance and ultimately the quality of patient care.”

    Amplichek I is an independent, multi-analyte quality control for the assessment of HIV-1, Hepatitis B (HBV) and Hepatitis C (HCV) nucleic acid tests that can help mitigate the limitations of manufacturer controls. Unlike some controls that are optimized for specific systems, Amplichek I can help reduce the risk associated with reporting inaccurate patient results by monitoring the performance of the complete analytical process and detecting lot-to-lot variation of assay reagents.
  • HERCULES, Calif. — October 24, 2016 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for its IH-1000 blood typing instrument along with approvals for a wide range of associated gel cards and reagents for the U.S. blood typing market. The system offers full automation and walk-away reliability, allowing laboratories to more efficiently manage their blood testing workload.

    With the release of the IH-1000 system and associated gel cards and reagents, Bio-Rad offers a wide variety of platforms, reagents, data management, and connectivity solutions to support different volume blood testing needs of the U.S. market. These products include Bio-Rad’s TANGO infinity™ system as well as a comprehensive range of reagents for conventional tube testing.

    "We are pleased the FDA has cleared the way for us to bring the IH-1000 and associated products to the U.S.,” said John Hertia, Bio-Rad Executive Vice President and President, Clinical Diagnostics Group. “With the availability of the IH-1000 system and gel cards, our TANGO infinity™ system, along with our comprehensive line of reagents, data management, and networking capability, customers now have the convenience and flexibility to select product solutions to optimize their laboratory workflow,” he added.

    The IH-1000 system includes the IH-1000 automated instrument, a wide range of gel cards, associated reagents, and IH-Com software for managing data and patient results and connections to the laboratory information system (LIS). The IH-1000 instrument is designed for rapid sample processing with continuous access, and it incorporates a number of important safety features. Together, these solutions offer our customers efficient and reliable results for blood grouping, reverse grouping, phenotyping, cross matching, antibody screening, antibody identification, direct AHG tests, and single antigen screens.

  • HERCULES, Calif. — June 12, 2017 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, today announced it has received U.S. Food and Drug Administration (FDA) clearance for its BioPlex® 2200 Syphilis Total & RPR assay, a novel one-step universal testing method to aid in the diagnosis of syphilis infection. 
    The BioPlex 2200 Syphilis Total & RPR (rapid plasma reagin) assay offers laboratories the first fully automated Treponemal/non-Treponemal dual assay, which simultaneously detects antibodies to T. pallidum and reagin antibodies as well as RPR titer (the level of antibody) determination for effective treatment monitoring. Compared to traditional manual RPR card tests, the automation of RPR testing offers labor savings, objective result reporting, and improved workflow to laboratories.
    “The addition of the BioPlex 2200 Syphilis Total & RPR assay broadens our expanding BioPlex 2200 System infectious disease menu while offering laboratories a simplified approach to syphilis testing, and it is adaptable to any testing algorithm used by a laboratory,“ said John Hertia, Bio-Rad President, Clinical Diagnostics Group.
    The release of the BioPlex 2200 Syphilis Total & RPR assay is the latest offering in Bio‑Rad’s growing infectious disease menu for the BioPlex® 2200 System, a fully automated multiplex technology platform. The BioPlex 2200 System provides clinical laboratories the capability to rapidly process or “multiplex” multiple individual tests that are traditionally processed separately, conserving patient sample volume and simplifying workflow.

 Products

  • NEW BioPlex 2200 Syphilis Total & RPR Assay
    The BioPlex 2200 Syphilis Total & RPR (Rapid Plasma Reagin) Assay offers laboratories the first fully automated Treponemal/Non-Treponemal dual assay, which simultaneously detects antibodies to T. pallidum and reagin antibodies as well as RPR titer determination....
       

  • The BioPlex 2200 Syphilis Total & RPR (Rapid Plasma Reagin) Assay offers laboratories the first fully automated Treponemal/Non-Treponemal dual assay, which simultaneously detects antibodies to T. pallidum and reagin antibodies as well as RPR titer determination.

    The addition of BioPlex 2200 Syphilis Total & RPR assay broadens Bio-Rad’s expanding BioPlex 2200 System Infectious Disease menu while providing laboratories the capability to rapidly process or multiplex individual tests that are traditionally processed separately. This assay design simplifies syphilis testing and is adaptable to any testing algorithm, providing more results with less effort. 

  • NEW BioPlex 2200 ToRC IgM Assay
    The BioPlex 2200 ToRC IgM Assay is a fully automated, multiplex flow immunoassay for the simultaneous identification and differentiation of IgM antibodies to T. gondii, Rubella and CMV, which are antibodies commonly tested in individuals suspected of having one of the respective disease states including women of child bearing age....
       

  • The BioPlex 2200 ToRC IgM Assay is a fully automated, multiplex flow immunoassay that targets IgM antibodies required for determining the serological status for Toxoplasma gondii (T. gondii), Rubella and Cytomegalovirus (CMV). This assay utilizes the diagnostic power of multiplex chemistry to simultaneously identify and differentiate antibodies, which is intended as an aid in the diagnosis of current or recent T. gondii, Rubella and/or CMV infection. 

    When used with the BioPlex 2200 ToRC IgG assay, the combination of BioPlex 2200 ToRC IgG and ToRC IgM assays offer a comprehensive testing solution for three of the most clinically significant diseases commonly tested in in women of child bearing age, providing more results with less effort.